GSK plcNYSE:GSK
- LAST PRICE36.6350
- TODAY'S CHANGE (%)-0.3350 (-0.9061%)
- Bid / Lots36.6300/ 1
- Ask / Lots36.6400/ 47
- Open / Previous Close36.6950 / 36.9700
- Day Range
- 52 Week Range
- Volume1,752,846
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GSK |
|---|---|---|
| 09:32 ET | 52070 | 36.59 |
| 09:33 ET | 43080 | 36.66 |
| 09:35 ET | 13677 | 36.566 |
| 09:37 ET | 19665 | 36.55 |
| 09:39 ET | 39487 | 36.6 |
| 09:42 ET | 128956 | 36.709 |
| 09:44 ET | 19730 | 36.66 |
| 09:46 ET | 13831 | 36.64 |
| 09:48 ET | 29077 | 36.59 |
| 09:50 ET | 39954 | 36.59 |
| 09:51 ET | 8099 | 36.57 |
| 09:53 ET | 11596 | 36.61 |
| 09:55 ET | 194343 | 36.635 |
| 09:57 ET | 11336 | 36.6509 |
| 10:00 ET | 3823 | 36.6499 |
| 10:02 ET | 17308 | 36.6 |
| 10:04 ET | 12253 | 36.6 |
| 10:06 ET | 5586 | 36.6 |
| 10:08 ET | 23838 | 36.56 |
| 10:09 ET | 3200 | 36.55 |
| 10:11 ET | 60246 | 36.595 |
| 10:13 ET | 59760 | 36.545 |
| 10:15 ET | 6415 | 36.535 |
| 10:18 ET | 9766 | 36.53 |
| 10:20 ET | 5713 | 36.535 |
| 10:22 ET | 4208 | 36.52 |
| 10:24 ET | 19198 | 36.495 |
| 10:26 ET | 8945 | 36.55 |
| 10:27 ET | 45194 | 36.53 |
| 10:29 ET | 3941 | 36.535 |
| 10:31 ET | 4012 | 36.535 |
| 10:33 ET | 11218 | 36.56 |
| 10:36 ET | 5011 | 36.545 |
| 10:38 ET | 10763 | 36.525 |
| 10:40 ET | 66716 | 36.585 |
| 10:42 ET | 5434 | 36.62 |
| 10:44 ET | 2950 | 36.635 |
| 10:45 ET | 26548 | 36.7 |
| 10:47 ET | 4212 | 36.72 |
| 10:49 ET | 7559 | 36.73 |
| 10:51 ET | 8283 | 36.72 |
| 10:54 ET | 20083 | 36.735 |
| 10:56 ET | 5555 | 36.71 |
| 10:58 ET | 16861 | 36.715 |
| 11:00 ET | 72952 | 36.68 |
| 11:02 ET | 9436 | 36.655 |
| 11:03 ET | 11076 | 36.67 |
| 11:05 ET | 8979 | 36.6607 |
| 11:07 ET | 18422 | 36.67 |
| 11:09 ET | 5492 | 36.66 |
| 11:12 ET | 7380 | 36.63 |
| 11:14 ET | 10005 | 36.6499 |
| 11:16 ET | 4193 | 36.635 |
| 11:18 ET | 3653 | 36.635 |
Oct 31, 2024
DJ AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update, from 3:48PM ET on Thursday Oct 31, 2024 by Dow Jones
3:48PM ET on Thursday Oct 31, 2024 by Dow JonesDJ GSK Cut to Neutral From Buy by Guggenheim, from 2:45PM ET on Thursday Oct 31, 2024 by Dow Jones
2:45PM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ GSK's 3Q Results Are a Mixed Bag -- Market Talk, from 11:04AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:04AM ET on Wednesday Oct 30, 2024 by Dow JonesDJ GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness -- Update, from 7:29AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:29AM ET on Wednesday Oct 30, 2024 by Dow JonesDJ GSK's Vaccine Weakness Is a Major Concern -- Market Talk, from 4:22AM ET on Wednesday Oct 30, 2024 by Dow Jones
4:22AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GSK plc | 75.8B | 23.2x | +6.39% |
Bristol-Myers Squibb Co | 112.4B | -15.4x | +4.90% |
Sanofi SA | 134.3B | 26.9x | +4.55% |
Bayer AG | 26.3B | -19.2x | --- |
Pfizer Inc | 157.3B | 37.4x | -7.10% |
Gilead Sciences Inc | 111.9B | 109.5x | +1.53% |
Company Information
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Contact Information
- Headquarters
- 980 Great West RoadBRENTFORD, United Kingdom TW8 9GS
- Phone
- 208-047-5000
- Fax
- 208-047-7807
Executives
- Independent Non-Executive Chairman of the Board
- Jonathan Symonds
- Chief Executive Officer, Executive Director
- Emma Walmsley
- Chief Financial Officer, Executive Director
- Julie Brown
- President - Corporate Development
- David Redfern
- President - Global Supply Chain
- Regis Simard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $75.8B |
|---|---|
Revenue (TTM) | $40.6B |
Shares Outstanding | 2.1B |
Dividend Yield | 4.29% |
Annual Dividend Rate | 1.5711 USD |
Ex-Dividend Date | 11-15-24 |
Pay Date | 01-09-25 |
Beta | 0.67 |
EPS | $1.58 |
Book Value | $8.53 |
P/E Ratio | 23.2x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | 10.4x |
Operating Margin | 12.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
